bluebird bio (BMV:BLUE *) - Cotización, noticias y análisis

Resumen de acción BLUE *

bluebird bio, Inc. es una empresa de biotecnología que investiga, desarrolla y comercializa en Estados Unidos terapias génicas para curar enfermedades genéticas graves. Saber más

Análisis fundamental de BLUE *
Puntuación del snowflake
Valoración	4/6
Crecimiento futuro	2/6
Rendimiento pasado	0/6
Salud financiera	0/6
Dividendos	0/6

Recompensas

Cotiza un 94.9% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los ingresos de 41.53%

Análisis de riesgos

Los accionistas han sido diluidos sustancialmente en el último año

Tiene menos de 1 año de cash runway

Patrimonio neto negativo

Acciones altamente ilíquidas

+ 3 riesgos adicionales

Competidores de bluebird bio, Inc.

Generation Bio

NasdaqGS:GBIO

US$93.5m

BioAtla

NasdaqGM:BCAB

US$80.3m

Coya Therapeutics

NasdaqCM:COYA

US$108.6m

X4 Pharmaceuticals

NasdaqCM:XFOR

US$57.2m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de bluebird bio
Precios históricos de las acciones
Precio actual de la acción	US$10.00
Máximo en las últimas 52 semanas	US$25.00
Mínimo de 52 semanas	US$9.50
Beta	0.80
1Cambio en 1 mes	0%
Variación en 3 meses	-17.36%
Cambio de 1 año	n/a
3Variación en 3 años	-95.58%
Variación en 5 años	-99.28%
Variación desde la OPV	-99.57%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	BLUE *	MX Biotechs	Mercado MX
7D	0%	0%	0%
1Y	n/a	0%	0%

Rentabilidad vs. Industria: Datos insuficientes para calcular los resultados de BLUE * en comparación con la industria MX Biotechs.

Rentabilidad vs. Mercado: Datos insuficientes para determinar el rendimiento de BLUE * frente al mercado MX.

Volatilidad de los precios

Is BLUE *'s price volatile compared to industry and market?
BLUE * volatility
BLUE * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Precio estable de las acciones: El precio de las acciones de BLUE * ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de BLUE * en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1992	282	Andrew Obenshain	www.bluebirdbio.com

bluebird bio, Inc, empresa de biotecnología, investiga, desarrolla y comercializa en Estados Unidos terapias génicas para enfermedades genéticas graves curativas. Los productos candidatos de la empresa para enfermedades genéticas graves incluyen ZYNTEGLO (betibeglogene autotemcel) para el tratamiento de la ß-talasemia dependiente de transfusión; lovotibeglogene autotemcel para el tratamiento de la anemia falciforme (ECF); y SKYSONA (elivaldogene autotemcel) para tratar la adrenoleucodistrofia cerebral. Sus programas de desarrollo clínico incluyen HGB-205, HGB-206 y HGB-210 para evaluar la seguridad y eficacia de lovo-cel en el tratamiento de pacientes con ECF; y HGB-204, HGB-205, HGB-207 y HGB-212 para evaluar la seguridad y eficacia de beti-cel en el tratamiento de pacientes con ß-talasemia.

Resumen de fundamentos de bluebird bio, Inc.

¿Cómo se comparan los beneficios e ingresos de bluebird bio con su capitalización de mercado?
Estadísticas fundamentales de BLUE *
Capitalización bursátil	Mex$1.49b
Beneficios(TTM)	-Mex$6.07b
Ingresos (TTM)	Mex$1.10b

1.4x

Ratio precio-ventas (PS)

-0.2x

Ratio precio-beneficio (PE)

¿Está BLUE * sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BLUE *
Ingresos	US$53.12m
Coste de los ingresos	US$78.78m
Beneficio bruto	-US$25.66m
Otros gastos	US$267.16m
Beneficios	-US$292.82m

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.51
Margen bruto	-48.31%
Margen de beneficio neto	-551.25%
Ratio deuda/patrimonio	-1,394.4%

¿Cómo se ha desempeñado BLUE * a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción BLUE *

Recompensas

Análisis de riesgos

Competidores de bluebird bio, Inc.

NasdaqGS:GBIO

US$93.5m

NasdaqGM:BCAB

US$80.3m

NasdaqCM:COYA

US$108.6m

NasdaqCM:XFOR

US$57.2m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.80 loss in 3Q 2023)

New major risk - Revenue and earnings growth

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

Recent updates

Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.80 loss in 3Q 2023)

New major risk - Revenue and earnings growth

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

Chief Medical Officer recently sold Mex$176k worth of stock

Chief Medical Officer recently sold Mex$176k worth of stock

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

Less than half of directors are independent

Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Less than half of directors are independent

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

Less than half of directors are independent

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

Treasurer recently sold Mex$1.6m worth of stock

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

President recently sold Mex$1.9m worth of stock

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021)

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

Chief Regulatory Officer recently sold Mex$140k worth of stock

Less than half of directors are independent

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Chief Commercial Officer recently sold Mex$226k worth of stock

Less than half of directors are independent

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

Bluebird Bio, Inc. Announces Executive Changes

bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022

bluebird bio, Inc. announced delayed annual 10-K filing

Less than half of directors are independent

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer

Less than half of directors are independent

bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)

Insider recently sold Mex$80k worth of stock

bluebird bio, Inc. to Launch Both beti-cel and eli-cel for Patients in the U.S. in Mid-2022

Insider recently sold Mex$637k worth of stock

Less than half of directors are independent